KURA · Kura Oncology, Inc.

Kura Oncology's Q1 2026 results mark the first full quarter of KOMZIFTI commercialization, generating $5.8 million in net product revenue with robust early indicators including 85 new patient starts, 157 total prescriptions, repeat use, switching from other menin inhibitors, and initial combination adoption. This reflects growing physician adoption in relapsed/refractory NPM1-mutant AML, supported by >93% payer coverage across over 12 million lives. CEO Troy Wilson highlighted these dynamics as signaling KOMZIFTI's potential leadership in this indication. Financially, total revenue rose to $18.3 million from $14.1 million year-over-year, driven by product sales offsetting a slight decline in collaboration revenue ($12.5 million vs. $14.1 million). Operating expenses increased significantly, with R&D up 17% to $65.3 million due to ziftomenib combination trials like KOMET-017, and SG&A up 38% to $31.6 million from commercialization investments, leading to a net loss of $73.3 million ($0.83 per share) versus $57.4 million ($0.66 per share) last year. Cash burned down to $580.8 million from $667.2 million at year-end, but combined with $180 million expected from Kyowa Kirin, funds the ziftomenib AML program through 2028 Phase 3 topline data. Pipeline momentum includes ongoing enrollment in multiple ziftomenib trials (KOMET-007, -008, -017, Japanese Phase 2) and darlifarnib progress, with several 2026 readouts like EHA oral presentation and ASCO data to drive catalysts.